This poster describes a study of a state Medicaid population, examining heart failure-related hospitalizations and emergency department(ED) visits to the treatment cost of managing heart failure pre- and post-sacubitril/valsartan initiation. Previous studies showed that patients who were treated with sacubitril/valsartan had lower rates of hospitalizations and costs. However, studies of the economic impact of sacubitril/valsartan for the Medicaid population is limited. This study concludes that the overall benefit (cost avoidance in hospitalizations/ED visits) did not outweigh the additional costs of sacubitril/valsartan. However, members that are more adherent to sacubitril/valsartan did have an overall benefit that outweighs the additional cost of sacubitril/valsartan.
Cost-Benefit Analysis of Sacubitril/Valsartan Among Patients with Heart Failure with Reduced Ejection Fraction in a Medicaid Population
Wednesday, April 22, 2020